Simsen® Personal
Simsen® Personal is a highly sensitive and patient-specific method to monitor circulating tumor DNA (ctDNA).

BIOPHARMA

Ultrasensitive ctDNA monitoring provides improved data precision, potential reductions in clinical trial costs, and validation of treatment efficacy.

ACADEMICS

Use ultrasensitive ctDNA analysis and gain deeper understanding of why some patients respond to treatment while others don’t.

SERVICE LABS

Provide personal ctDNA analysis as a tool to your partners and customers for improving cancer diagnostics and treatment monitoring.

BIOPHARMA

Ultrasensitive ctDNA monitoring provides improved data precision, potential reductions in clinical trial costs, and validation of treatment efficacy.

ACADEMICS

Use ultrasensitive ctDNA analysis and gain deeper understanding of why some patients respond to treatment while others don’t.

SERVICE LABS

Provide personal ctDNA analysis as a tool to your partners and customers for improving cancer diagnostics and treatment monitoring.

BIOPHARMA

Ultrasensitive ctDNA monitoring provides improved data precision, potential reductions in clinical trial costs, and validation of treatment efficacy.

ACADEMICS

Use ultrasensitive ctDNA analysis and gain deeper understanding of why some patients respond to treatment while others don’t.

SERVICE LABS

Provide personal ctDNA analysis as a tool to your partners and customers for improving cancer diagnostics and treatment monitoring.

Simsen® Personal for ultrasensitive ctDNA monitoring

The patient-specific ctDNA detection approach of Simsen® Personal is used to monitor the unique genetic characteristics of an individual’s tumor. It enables accurate tracking of treatment efficacy, early resistance detection, minimal residual disease (MRD) monitoring, and optimization for follow-up care plans for better patient outcomes.

Want to know more?

Let’s set up a meeting to discuss how Simsen® Personal can assist you.

What is circulating tumor DNA?

Circulating tumor DNA (ctDNA) refers to small fragments of DNA that come from dead tumor cells and are found in the bloodstream. These DNA fragments circulate within the bloodstream alongside DNA from healthy cells. The ctDNA contains distinct genetic mutations or changes that are unique to the tumor they originated from.

Why use ctDNA in cancer monitoring?

ctDNA, unlike protein-based biomarkers, is a tumor-specific biomarker, indicating (true) remaining disease within the body. With the help of ctDNA, cancer can be detected years earlier, compared to using standard-of-care tools, such as imaging. Moreover, monitoring ctDNA helps understand tumor genetics, track treatment response or disease progress, and detect minimal residual disease (MRD). Analysis of ctDNA offers a non-invasive way to gather crucial information for cancer diagnosis and management.

Personalization is the key to sensitivity

Why does personal matter?

Personalized ctDNA tests are tailored to the individual’s cancer. A sample of the patient’s tumor is used to identify unique mutations. This personalized approach means the test can identify many more mutations or changes that are unique to the tumor with the following benefits:

Ultrasensitive

Because these tests are searching for specific mutations known to be present in a patient’s tumor, they can be more sensitive in detecting low levels of ctDNA. This can be particularly advantageous in early detection, minimal residual disease monitoring, or assessing response to therapy.

Patient Specific

Tumors are often heterogeneous, meaning they have a variety of different mutations. A fixed sequencing panel may not cover all the relevant mutations present in a particular patient’s tumor. A tumor-informed test, however, is designed based on the full spectrum of mutations in an individual’s tumor, making it more representative of the tumor and more likely to detect ctDNA.

Persistent Monitoring

Tumors can evolve over time, especially under treatment pressure. A tumor-informed test is less biased to selection pressures whereas a fixed panel may become less relevant as the tumor evolves.

Ultrasensitive

Because these tests are searching for specific mutations known to be present in a patient’s tumor, they can be more sensitive in detecting low levels of ctDNA. This can be particularly advantageous in early detection, minimal residual disease monitoring, or assessing response to therapy.

Patient Specific

Tumors are often heterogeneous, meaning they have a variety of different mutations. A fixed sequencing panel may not cover all the relevant mutations present in a particular patient’s tumor. A tumor-informed test, however, is designed based on the full spectrum of mutations in an individual’s tumor, making it more representative of the tumor and more likely to detect ctDNA.

Persistent Monitoring

Tumors can evolve over time, especially under treatment pressure. A tumor-informed test is less biased to selection pressures whereas a fixed panel may become less relevant as the tumor evolves.

Ultrasensitive

Because these tests are searching for specific mutations known to be present in a patient’s tumor, they can be more sensitive in detecting low levels of ctDNA. This can be particularly advantageous in early detection, minimal residual disease monitoring, or assessing response to therapy.

Patient Specific

Tumors are often heterogeneous, meaning they have a variety of different mutations. A fixed sequencing panel may not cover all the relevant mutations present in a particular patient’s tumor. A tumor-informed test, however, is designed based on the full spectrum of mutations in an individual’s tumor, making it more representative of the tumor and more likely to detect ctDNA.

Persistent Monitoring

Tumors can evolve over time, especially under treatment pressure. A tumor-informed test is less biased to selection pressures whereas a fixed panel may become less relevant as the tumor evolves.

FDA recommends ctDNA in clinical trials

Limitations of traditional fixed panels

Fixed sequencing panels test for a predetermined set of mutations. If a patient’s tumor has unique or rare mutations not included in the panel, they won’t be detected. This limitation can lead to a lower sensitivity compared to a tumor-informed approach. Especially for rare, less-studied cancers.

Simsen® Personal offers exceptional sensitivity without unnecessary complexity

By prioritizing sensitivity while optimizing complexity, Simsen® Personal aligns with the evolving needs of researchers, clinicians, and biopharmaceutical professionals

Flexible process for elevated insights

Simsen® Personal delivers advanced ctDNA data for insights in clinical studies and trials. The process starts with a tumor biopsy and plasma sample, followed by Simsen Diagnostics designing a personalized assay. This flexible workflow allows testing multiple samples at different time points on the same platform, providing crucial insights over time for improved treatment assessments.

News and publications

Previous slide
Next slide

Learn more

Circulating tumor DNA as a biomarker in clinical trials

White Paper

FDA recommends ctDNA in clinical trials

Pontus Rehn

Chief Executive Officer (CEO)

Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy. 

Lina Said

Laboratory and Quality Manager

Lina Said, a licensed Biomedical Scientist, brings 18 years of experience from Sahlgrenska University Hospital to her role as the Lab and Quality Manager at Simsen Diagnostics. Her primary focus is ensuring quality assurance and fostering an optimal work environment for the lab. 

My Vu

Lead Laboratory Technician

My Vu is currently doing a master’s degree in biotechnology and demonstrates expertise in laboratory procedures. Her previous experience includes analyzing COVID samples and conducting her bachelor’s thesis at Fraunhofer. My is analyzing all the samples that comes to the lab.  

Stefan Filges

Chief Technology Officer (CTO)

Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols. 

Camilla Hietanen

Head of Sales and Marketing

Camilla Hietanen holds an M.Sc. in Business Development from the Chalmers School of Entrepreneurship. Her academic background encompasses studies in Sports & Nutrition, and she brings prior experience from various Start-ups. Within Simsen Diagnostics, her primary focus lies in Sales and Marketing. 

Almost there

Sign up on our maillist to gain access to your article. You can at any time unsubscribe from the list.